Show simple item record

dc.contributor.authorLaxy, Michaelen
dc.contributor.authorWilson, Eden
dc.contributor.authorBoothby, Clareen
dc.contributor.authorGriffin, Simonen
dc.date.accessioned2017-08-22T10:19:37Z
dc.date.available2017-08-22T10:19:37Z
dc.date.issued2017-12en
dc.identifier.issn1098-3015
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/266711
dc.description.abstractBackground: There is uncertainty about the cost-effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening. Objectives: To derive a trial-informed estimate of the incremental costs of intensive treatment as delivered in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care-Europe (ADDITION) trial and to revisit the long-term cost-effectiveness analysis from the perspective of the UK National Health Service. Methods: We analyzed the electronic primary care records of a subsample of the ADDITION-Cambridge trial cohort (n = 173). Unit costs of used primary care services were taken from the published literature. Incremental annual costs of intensive treatment versus routine care in years 1 to 5 after diagnosis were calculated using multilevel generalized linear models. We revisited the long-term cost-utility analyses for the ADDITION-UK trial cohort and reported results for ADDITION-Cambridge using the UK Prospective Diabetes Study Outcomes Model and the trial-informed cost estimates according to a previously developed evaluation framework. Results: Incremental annual costs of intensive treatment over years 1 to 5 averaged £29.10 (standard error = £33.00) for consultations with general practitioners and nurses and £54.60 (standard error = £28.50) for metabolic and cardioprotective medication. For ADDITION-UK, over the 10-, 20-, and 30-year time horizon, adjusted incremental quality-adjusted life-years (QALYs) were 0.014, 0.043, and 0.048, and adjusted incremental costs were £1,021, £1,217, and £1,311, resulting in incremental cost-effectiveness ratios of £71,232/QALY, £28,444/QALY, and £27,549/QALY, respectively. Respective incremental cost-effectiveness ratios for ADDITION-Cambridge were slightly higher. Conclusions: The incremental costs of intensive treatment as delivered in the ADDITION-Cambridge trial were lower than expected. Given UK willingness-to-pay thresholds in patients with screen-detected diabetes, intensive treatment is of borderline cost-effectiveness over a time horizon of 20 years and more.
dc.description.sponsorshipADDITION-Cambridge was supported by the Wellcome Trust (grant reference No G061895) the Medical Research Council (grant reference no: G0001164), National Health Service R&D support funding (including the Primary Care Research and Diabetes Research Networks), and the National Institute for Health Research. We received an unrestricted grant from University of Aarhus, Denmark, to support the ADDITION-Cambridge trial. Bio-Rad provided equipment to undertake capillary glucose screening by HbA1c in general practice. SG is a National Institute for Health Research (NIHR) Senior Investigator. The Primary Care Unit is supported by NIHR Research funds. SJG received support from the Department of Health NIHR Programme Grant funding scheme (RP-PG-0606-1259).
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.language.isoenen
dc.publisherElsevier
dc.subjectHumansen
dc.subjectDiabetes Mellitus, Type 2en
dc.subjectMass Screeningen
dc.subjectLinear Modelsen
dc.subjectProspective Studiesen
dc.subjectQuality-Adjusted Life Yearsen
dc.subjectTime Factorsen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectMiddle Ageden
dc.subjectCost-Benefit Analysisen
dc.subjectHealth Care Costsen
dc.subjectPrimary Health Careen
dc.subjectFemaleen
dc.subjectMaleen
dc.subjectUnited Kingdomen
dc.titleIncremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.en
dc.typeArticle
prism.endingPage1298
prism.issueIdentifier10en
prism.publicationDate2017en
prism.publicationNameValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Researchen
prism.startingPage1288
prism.volume20en
dc.identifier.doi10.17863/CAM.12784
dcterms.dateAccepted2017-05-28en
rioxxterms.versionofrecord10.1016/j.jval.2017.05.018en
rioxxterms.versionAMen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2017-12en
dc.contributor.orcidWilson, Edward [0000-0002-8369-1577]
dc.contributor.orcidBoothby, Clare [0000-0001-9396-8333]
dc.contributor.orcidGriffin, Simon [0000-0002-2157-4797]
dc.identifier.eissn1524-4733
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idNIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/08/116/300)
pubs.funder-project-idMRC (MC_UU_12015/4)
pubs.funder-project-idNIHR Central Commissioning Facility (NIHRDH-RP-PG-0606-1259)
pubs.funder-project-idMRC (G0001164)
pubs.funder-project-idWellcome Trust (061895/Z/00/Z)
rioxxterms.freetoread.startdate2018-07-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record